Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Neoplasm Metastasis 2Nasopharyngeal Carcinoma 1Advanced Solid Tumor 1Advanced Malignant Tumors 1

Interventions

Gemcitabine 6pembrolizumab 5toripalimab 2fludarabine 2Valproic Acid 2Valganciclovir 2Injections 2Cyclophosphamide 2Cisplatin 2130-nm albumin-bound paclitaxel 2tislelizumab 1spartalizumab 1sapropterin 1fosaprepitant 1fludarabine phosphate 1camrelizumab 1Surgical Procedures, Operative 1Specimen Handling 1SHR-1701 1Protons 1Proton Therapy 1Panobinostat 1Medicare Part B 1Magnetic Resonance Spectroscopy 1Ipilimumab 1Interleukin-2 1Floxuridine 1Everolimus 1Dexamethasone 1Chemoradiotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Nasopharyngeal Carcinoma × SHR-1701 × Clear all
NCT04282070 2021-12-21

SHR-1701 in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Unknown
91 enrolled
Head & Neck

Nasopharyngeal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡